<!DOCTYPE html>
<html><head><style>table, th, td {border: 1px solid black;border-collapse: collapse;}</style></head>
<table colsep="0" frame="topbot" id="tbl0010" trsep="0" xmlns="http://www.elsevier.com/xml/common/cals/dtd">
<label>
        Table 2
       </label>
<caption id="cap0025">
<simple-para id="spar0030" view="all">
         Summary of relative treatment effects in aBSI quartiles for overall and failure-free survival.
        </simple-para>
</caption>

<tgroup cols="4">
<colspec colname="col1"/>
<colspec colname="col2"/>
<colspec colname="col3"/>
<colspec colname="col4"/>
<thead valign="top">
<tr>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd"/>
<td align="left" colspan="2" nameend="col3" namest="col2" trsep="1" xmlns="http://www.elsevier.com/xml/common/dtd">
           No. of events/no. of patients
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Hazard ratio (95% CI)
           
</td>
</tr>
<tr trsep="1">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd"/>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           SOC
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           SOC + RT
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left" role="trhead" xmlns="http://www.elsevier.com/xml/common/dtd">
           Overall survival
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd"/>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd"/>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd"/>
</tr>
<tr>
<td align="left" role="trhead" xmlns="http://www.elsevier.com/xml/common/dtd">
<hsp sp="1.0"/>
           aBSI quartile 1
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           29/79
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           19/89
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           0.50 (0.28–0.91)
          </td>
</tr>
<tr>
<td align="left" role="trhead" xmlns="http://www.elsevier.com/xml/common/dtd">
<hsp sp="1.0"/>
           aBSI quartile 2
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           17/78
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           23/88
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           1.06 (0.54–2.08)
          </td>
</tr>
<tr>
<td align="left" role="trhead" xmlns="http://www.elsevier.com/xml/common/dtd">
<hsp sp="1.0"/>
           aBSI quartile 3
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           32/84
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           32/78
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           1.00 (0.60–1.64)
          </td>
</tr>
<tr>
<td align="left" role="trhead" xmlns="http://www.elsevier.com/xml/common/dtd">
<hsp sp="1.0"/>
           aBSI quartile 4
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           45/82
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           46/82
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           1.10 (0.72–1.69)
          </td>
</tr>
<tr>
<td align="left" role="trhead" xmlns="http://www.elsevier.com/xml/common/dtd">
           Failure-free survival
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd"/>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd"/>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd"/>
</tr>
<tr>
<td align="left" role="trhead" xmlns="http://www.elsevier.com/xml/common/dtd">
<hsp sp="1.0"/>
           aBSI quartile 1
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           54/79
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           36/89
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           0.35 (0.22–0.54)
          </td>
</tr>
<tr>
<td align="left" role="trhead" xmlns="http://www.elsevier.com/xml/common/dtd">
<hsp sp="1.0"/>
           aBSI quartile 2
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           55/78
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           50/88
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           0.67 (0.44–1.00)
          </td>
</tr>
<tr>
<td align="left" role="trhead" xmlns="http://www.elsevier.com/xml/common/dtd">
<hsp sp="1.0"/>
           aBSI quartile 3
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           66/84
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           60/78
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           0.81 (0.56–1.16)
          </td>
</tr>
<tr>
<td align="left" role="trhead" xmlns="http://www.elsevier.com/xml/common/dtd">
<hsp sp="1.0"/>
           aBSI quartile 4
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           70/82
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           73/82
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           1.08 (0.76–1.52)
          </td>
</tr>
</tbody>
</tgroup>
<legend>
<simple-para id="spar0035" view="all">
         aBSI = automated bone scan index; CI = confidence interval; NSAID = nonsteroidal anti-inflammatory drug; RT = radiotherapy; SOC = standard of care; WHO PS = World Health Organization performance status.
        </simple-para>
</legend>
<table-footnote id="tblfn0010">

<note-para id="npar0010" view="all">
         Adjusted for age (&lt;70 or ≥70 yr), N stage (N0, N+, or NX), WHO PS (0 or 1–2), NSAID or aspirin use (uses either or none of these), and planned docetaxel use (yes or no).
        </note-para>
</table-footnote>
</table>
</html>
